Cytokinetics

YTD

ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

673

Employees673

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

673

Employees673

CYTK Key Statistics

Market cap

10.23B

Market cap10.23B

Price-Earnings ratio

-10.79

Price-Earnings ratio-10.79

Dividend yield

—

Dividend yield—

Average volume

1.44M

Average volume1.44M

High today

$78.89

High today$78.89

Low today

$72.86

Low today$72.86

Open price

$74.36

Open price$74.36

Volume

189.74K

Volume189.74K

52 Week high

$88.31

52 Week high$88.31

52 Week low

$35.22

52 Week low$35.22

Stock Snapshot

With a market cap of 10.23B, Cytokinetics(CYTK) trades at $73.60. The stock has a price-to-earnings ratio of -10.79.

During the trading session on 2026-08-28, Cytokinetics(CYTK) shares reached a daily high of $78.89 and a low of $72.86. At a current price of $73.60, the stock is +1.0% higher than the low and still -6.7% under the high.

Trading activity shows a volume of 189.74K, compared to an average daily volume of 1.44M.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $35.22.

CYTK News

TipRanks 3h

Cytokinetics reports ACACIA-HCM trial met both primary endpoints

Cytokinetics (CYTK) announced the primary results from ACACIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertro...

Simply Wall St 6d

Cytokinetics Could Be 29% Undervalued Following Favorable Phase 3 Aficamten Data

Cytokinetics (CYTK) has drawn fresh attention after disclosing that it will present favorable topline results from its ACACIA-HCM Phase 3 aficamten trial at the...

Nasdaq 6d

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 Key Points The transaction involved the disposal of 7,500 shares. The disposi...

Analyst ratings

91%

of 23 ratings

Buy

91.3%

Hold

8.7%

Sell

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.